undisclosed
Our investment in Currus Biologics: Unlocking CAR-T for Solid Tumours
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.